{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:02:52Z","timestamp":1789394572472,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40259-026-00801-0","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T08:47:53Z","timestamp":1785746873000},"page":"925-935","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Outcomes After Week-12 Response-Guided Secukinumab Discontinuation in Psoriasis: A Prospective Real-World Cohort Study"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"chictr2200066894","registry":"10.18810\/chictr"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-1924","authenticated-orcid":false,"given":"Xin","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanruo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanlingzi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"issue":"19","key":"801_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis. JAMA. 2020;323(19):1945. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"issue":"4","key":"801_CR2","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/bjd.19325","volume":"183","author":"SK Mahil","year":"2020","unstructured":"Mahil SK, Ezejimofor MC, Exton LS, et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol. 2020;183(4):638\u201349. https:\/\/doi.org\/10.1111\/bjd.19325.","journal-title":"Br J Dermatol"},{"issue":"2","key":"801_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","volume":"66","author":"K Gordon","year":"2012","unstructured":"Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66(2):241\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2010.12.005.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"801_CR4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1080\/09546634.2020.1869147","volume":"33","author":"S Atalay","year":"2022","unstructured":"Atalay S, van den Reek JMPA, Groenewoud JMM, van de Kerkhof PCM, Kievit W, de Jong EMGJ. Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice. J Dermatol Treat. 2022;33(3):1591\u20137. https:\/\/doi.org\/10.1080\/09546634.2020.1869147.","journal-title":"J Dermatol Treat"},{"issue":"6 Suppl 1","key":"801_CR5","first-page":"S7","volume":"9","author":"AW Armstrong","year":"2016","unstructured":"Armstrong AW, Papp K, Kircik L. Secukinumab: review of clinical evidence from the pivotal studies ERASURE, FIXTURE, and CLEAR. J Clin Aesthet Dermatol. 2016;9(6 Suppl 1):S7\u201312.","journal-title":"J Clin Aesthet Dermatol."},{"issue":"5","key":"801_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/bjd\/ljad248","volume":"189","author":"C Marcombes","year":"2023","unstructured":"Marcombes C, Penso L, Weill A, Dray-Spira R, Zureik M, Sbidian E. Persistence of second-line biologics in psoriasis after first-line biologic failure: a nationwide cohort study from the French health insurance database (SNDS). Br J Dermatol. 2023;189(5):561\u20138. https:\/\/doi.org\/10.1093\/bjd\/ljad248.","journal-title":"Br J Dermatol"},{"key":"801_CR7","doi-asserted-by":"publisher","unstructured":"Chinese Society of Dermatology, China Dermatologist Association, Dermatology & Venereology Specialized Committee of Chinese Association of Integrative Medicine. Guidelines for the treatment of psoriasis with biologics and small-molecule drugs in China (2024) [in Chinese]. Chin J Dermatol. 2024;57(11):976\u201397. https:\/\/doi.org\/10.35541\/cjd.20240294.","DOI":"10.35541\/cjd.20240294"},{"issue":"1","key":"801_CR8","doi-asserted-by":"publisher","first-page":"2154570","DOI":"10.1080\/09546634.2022.2154570","volume":"34","author":"LS van der Schoot","year":"2023","unstructured":"van der Schoot LS, Baerveldt EM, van Enst WA, et al. National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure. J Dermatol Treat. 2023;34(1):2154570. https:\/\/doi.org\/10.1080\/09546634.2022.2154570.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"801_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.17738","volume":"181","author":"A Mourad","year":"2019","unstructured":"Mourad A, Straube S, Armijo\u2010Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta\u2010analysis. Br J Dermatol. 2019;181(3):450\u20138. https:\/\/doi.org\/10.1111\/bjd.17738.","journal-title":"Br J Dermatol"},{"issue":"4","key":"801_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40257-022-00679-y","volume":"23","author":"M Masson Regnault","year":"2022","unstructured":"Masson Regnault M, Shourick J, Jendoubi F, Tauber M, Paul C. Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review. Am J Clin Dermatol. 2022;23(4):433\u201347. https:\/\/doi.org\/10.1007\/s40257-022-00679-y.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"801_CR11","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jaad.2023.01.029","volume":"88","author":"ML Nielsen","year":"2023","unstructured":"Nielsen ML, Thein D, Rasmussen MK, et al. Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: a nationwide cohort study. J Am Acad Dermatol. 2023;88(6):1378\u201381. https:\/\/doi.org\/10.1016\/j.jaad.2023.01.029.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"801_CR12","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1001\/jamadermatol.2025.0669","volume":"161","author":"BN Rome","year":"2025","unstructured":"Rome BN, Han J, Mooney H, Kesselheim AS. Use and cost of first-line biologic medications to treat plaque psoriasis in the US. JAMA Dermatol. 2025;161(6):622. https:\/\/doi.org\/10.1001\/jamadermatol.2025.0669.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"801_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jaad.2022.06.1164","volume":"88","author":"D Patel","year":"2023","unstructured":"Patel D, Svoboda R, Maczuga S, Foulke GT, Helm M. A retrospective claims analysis confirms the cost of most biologic agents for psoriasis is increasing more rapidly than medical inflation. J Am Acad Dermatol. 2023;88(2):490\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.1164.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"801_CR14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40261-023-01280-9","volume":"43","author":"P Herranz-Pinto","year":"2023","unstructured":"Herranz-Pinto P, Alonso-Pacheco ML, Feltes-Ochoa R, et al. Real-world performance of a new strategy for off-label use of guselkumab in moderate to severe psoriasis: super-responder patients as the epitome of efficacy and optimisation. Clin Drug Investig. 2023;43(7):517\u201327. https:\/\/doi.org\/10.1007\/s40261-023-01280-9.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"801_CR15","doi-asserted-by":"publisher","first-page":"adv00463","DOI":"10.2340\/00015555-3815","volume":"101","author":"S Atalay","year":"2021","unstructured":"Atalay S, Schoot L, Vandermaesen L, et al. Evaluation of a one-step dose reduction strategy of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily practice. Acta Derm Venereol. 2021;101(5):adv00463. https:\/\/doi.org\/10.2340\/00015555-3815.","journal-title":"Acta Derm Venereol"},{"issue":"19","key":"801_CR16","doi-asserted-by":"publisher","first-page":"adv00340","DOI":"10.2340\/00015555-3692","volume":"100","author":"S Atalay","year":"2020","unstructured":"Atalay S, Reek J, Otero M, et al. Health economic consequences of a tightly controlled dose reduction strategy for adalimumab, etanercept and ustekinumab compared with standard psoriasis care: a cost-utility analysis of the CONDOR study. Acta Derm Venereol. 2020;100(19):adv00340. https:\/\/doi.org\/10.2340\/00015555-3692.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"801_CR17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jaad.2019.01.035","volume":"88","author":"HY Chiu","year":"2023","unstructured":"Chiu HY, Hui RC, Tsai TF, et al. Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: an 8-year multicenter study. J Am Acad Dermatol. 2023;88(1):71\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2019.01.035.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"801_CR18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/09546634.2020.1759769","volume":"33","author":"A Di Altobrando","year":"2022","unstructured":"Di Altobrando A, Magnano M, Offidani A, et al. Deferred time of delivery of biologic therapies in patients with stabilized psoriasis leads to a \u2018perceived satisfaction\u2019: a multicentric study. J Dermatol Treat. 2022;33(1):415\u20139. https:\/\/doi.org\/10.1080\/09546634.2020.1759769.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"801_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/17512433.2025.2527098","volume":"18","author":"N Akdogan","year":"2025","unstructured":"Akdogan N, Mutlu \u00d6K, Karabulut E, Yalici-Armagan B, Gulseren D, Dogan Gunayd\u0131n S. Early response is a strong predictor of the long-term response in psoriasis patients receiving risankizumab or guselkumab in the real-world: a retrospective analysis. Expert Rev Clin Pharmacol. 2025;18(6):417\u201323. https:\/\/doi.org\/10.1080\/17512433.2025.2527098.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"801_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.36849\/JDD.6063","volume":"21","author":"M Augustin","year":"2022","unstructured":"Augustin M, Gallo G, See K, et al. Early response is associated with stable long-term response in psoriasis patients receiving ixekizumab or ustekinumab. J Drugs Dermatol. 2022;21(2):122\u20136. https:\/\/doi.org\/10.36849\/JDD.6063.","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"801_CR21","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jaad.2025.06.019","volume":"93","author":"J Chen","year":"2025","unstructured":"Chen J, Zhou G, Sha Y, et al. Disease modification in psoriasis through early interleukin 17 inhibitor intervention: a retrospective cohort study. J Am Acad Dermatol. 2025;93(4):1000\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2025.06.019.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"801_CR22","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jaad.2025.01.055","volume":"92","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Yao L, Zhong X, et al. Early inadequate response to biological agents portends treatment failure at 6 months in patients with psoriasis: a multicenter, prospective cohort study. J Am Acad Dermatol. 2025;92(5):1153\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2025.01.055.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"801_CR23","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398. https:\/\/doi.org\/10.1111\/jdv.16915.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"801_CR24","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"key":"801_CR25","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/PTT.S534032","volume":"15","author":"F Shen","year":"2025","unstructured":"Shen F, Ding Y, Qiang Y, et al. Tobacco smoking was positively associated with disease relapse at week 24 and 48 among patients with psoriasis vulgaris in Shanghai: a prospective study. Psoriasis (Auckl). 2025;15:261\u201372. https:\/\/doi.org\/10.2147\/PTT.S534032.","journal-title":"Psoriasis (Auckl)."},{"issue":"4","key":"801_CR26","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bjd.19039","volume":"183","author":"CH Smith","year":"2020","unstructured":"Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628\u201337. https:\/\/doi.org\/10.1111\/bjd.19039.","journal-title":"Br J Dermatol"},{"issue":"1","key":"801_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","volume":"73","author":"U Mrowietz","year":"2015","unstructured":"Mrowietz U, Leonardi CL, Girolomoni G, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27-36.e1. https:\/\/doi.org\/10.1016\/j.jaad.2015.04.011.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"801_CR28","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.jaad.2016.01.048","volume":"74","author":"JA Doshi","year":"2016","unstructured":"Doshi JA, Takeshita J, Pinto L, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057-1065.e4. https:\/\/doi.org\/10.1016\/j.jaad.2016.01.048.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"801_CR29","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.adengl.2020.05.003","volume":"111","author":"DP Ruiz-Genao","year":"2020","unstructured":"Ruiz-Genao DP, Carretero G, Rivera R, et al. Changing trends in drug prescription and causes of treatment discontinuation of first biologic over ten years in psoriasis in the Spanish Biobadaderm registry. Actas Dermo-Sifiliogr\u00e1ficas (Engl Edn). 2020;111(9):752\u201360. https:\/\/doi.org\/10.1016\/j.adengl.2020.05.003.","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (Engl Edn)"},{"issue":"2","key":"801_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/bjd\/ljae068","volume":"191","author":"D Gleeson","year":"2024","unstructured":"Gleeson D, Naveed M, Moorhead L, et al. Acceptability of \u2018as needed\u2019 biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study. Br J Dermatol. 2024;191(2):243\u201351. https:\/\/doi.org\/10.1093\/bjd\/ljae068.","journal-title":"Br J Dermatol"},{"issue":"3","key":"801_CR31","doi-asserted-by":"publisher","first-page":"e2024166","DOI":"10.5826\/dpc.1403a166","volume":"14","author":"A Dattola","year":"2024","unstructured":"Dattola A, Bernardini N, Caldarola G, et al. Effectiveness of ixekizumab in elderly patients for the treatment of moderate-to-severe psoriasis: results from a multicenter, retrospective real-life study in the Lazio region. Dermatol Pract Concept. 2024;14(3):e2024166. https:\/\/doi.org\/10.5826\/dpc.1403a166.","journal-title":"Dermatol Pract Concept"},{"key":"801_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2025-5-1","volume":"14","author":"A Dattola","year":"2025","unstructured":"Dattola A, Bernardini N, Anedda J, et al. Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms. Drugs Context. 2025;14:1\u201310. https:\/\/doi.org\/10.7573\/dic.2025-5-1.","journal-title":"Drugs Context"},{"issue":"4","key":"801_CR33","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1504a6646","volume":"15","author":"N Bernardini","year":"2025","unstructured":"Bernardini N, Caldarola G, Richetta AG, et al. Long-term persistence with guselkumab: a 5-year multicenter retrospective study across 14 dermatology centers in Italy. Dermatol Pract Concept. 2025;15(4):6646. https:\/\/doi.org\/10.5826\/dpc.1504a6646.","journal-title":"Dermatol Pract Concept"},{"key":"801_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1488096","volume":"11","author":"S Huang","year":"2024","unstructured":"Huang S, Chen B, Qi Y, Duan X, Bai Y. Development and external validation of a prediction model for the risk of relapse in psoriasis after discontinuation of biologics. Front Med. 2024;11:1488096. https:\/\/doi.org\/10.3389\/fmed.2024.1488096.","journal-title":"Front Med"},{"issue":"11","key":"801_CR35","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1007\/s13555-023-01028-5","volume":"13","author":"RR McLean","year":"2023","unstructured":"McLean RR, Sima AP, Beaty S, et al. Durability of near-complete skin clearance in patients with psoriasis using systemic biologic therapies: real-world evidence from the CorEvitas Psoriasis Registry. Dermatol Ther (Heidelb). 2023;13(11):2753\u201368. https:\/\/doi.org\/10.1007\/s13555-023-01028-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"801_CR36","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jaad.2024.12.016","volume":"92","author":"J Burshtein","year":"2025","unstructured":"Burshtein J, Armstrong A, Chow M, et al. The association between obesity and efficacy of psoriasis therapies: an expert consensus panel. J Am Acad Dermatol. 2025;92(4):807\u201315. https:\/\/doi.org\/10.1016\/j.jaad.2024.12.016.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"801_CR37","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.immuni.2023.06.021","volume":"56","author":"P Sivasami","year":"2023","unstructured":"Sivasami P, Elkins C, Diaz-Saldana PP, et al. Obesity-induced dysregulation of skin-resident PPAR\u03b3+ Treg cells promotes IL-17A-mediated psoriatic inflammation. Immunity. 2023;56(8):1844-1861.e6. https:\/\/doi.org\/10.1016\/j.immuni.2023.06.021.","journal-title":"Immunity"},{"issue":"6","key":"801_CR38","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41423-025-01278-7","volume":"22","author":"Y Xia","year":"2025","unstructured":"Xia Y, Lan J, Yang J, et al. Saturated fatty acid-induced neutrophil extracellular traps contribute to exacerbation and biologic therapy resistance in obesity-related psoriasis. Cell Mol Immunol. 2025;22(6):597\u2013611. https:\/\/doi.org\/10.1038\/s41423-025-01278-7.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"801_CR39","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jamadermatol.2025.0288","volume":"161","author":"HJ Kim","year":"2025","unstructured":"Kim HJ, Lee EH, Jung Y. Association of obesity and innate immune markers with resistance to biologic therapy in psoriasis. JAMA Dermatol. 2025;161(6):629. https:\/\/doi.org\/10.1001\/jamadermatol.2025.0288.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"801_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/bjd\/ljae163","volume":"191","author":"C N\u00e4slund-Koch","year":"2024","unstructured":"N\u00e4slund-Koch C, Skov L. Shedding light on the smoke: unravelling the impact of smoking cessation on psoriasis development. Br J Dermatol. 2024;191(2):157\u20138. https:\/\/doi.org\/10.1093\/bjd\/ljae163.","journal-title":"Br J Dermatol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00801-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00801-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:03:21Z","timestamp":1789391001000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00801-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00801-0","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"21 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest relevant to this work.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data for this study are available upon request from the corresponding author. The request should state the title and aim of the research for which the data are requested.","order":2,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Ethics Committee of Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China (2022-38). The study was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written patient consent was obtained before starting the study.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain identifiable individual patient data or identifiable clinical images.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No custom code or software application was developed for this study. Statistical analyses were performed using SAS version 9.4.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xin Ma, Ruiping Wang, and Bin Li contributed to the conception and design of the study. Xin Ma, Yue Jiang, Dongmei Liu, Quanruo Xu, Fanlingzi Shen, Zhen Duan, Xiangjin Gao, Xiuqi Zhang, Ruiqi Cai, and Rui Zhang contributed to data collection, data curation, and clinical assessment. Yue Jiang, Dongmei Liu, Quanruo Xu, and Fanlingzi Shen contributed to statistical analysis and interpretation of data. Xin Ma drafted the manuscript. Ruiping Wang and Bin Li critically revised the manuscript for important intellectual content and supervised the study. All authors read and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}